Patient’s travel distance to specialised cancer diagnostics and the association with the general practitioner’s diagnostic strategy and satisfaction with the access to diagnostic procedures: an observational study in Denmark

CURRENT STATUS: UNDER REVISION

BMC Family Practice

Line Flytkjær Virgilsen
Research unit for general practice

✉ line.virgilsen@ph.au.dk

Corresponding Author
ORCID: https://orcid.org/0000-0002-4877-2697

Line Hvidberg
Hospital of Southern Denmark

Peter Vedsted
Research Unit for General Practice

DOI:
10.21203/rs.2.24205/v1

SUBJECT AREAS
General Biochemistry

KEYWORDS
General practice, travel distance, diagnostic strategy, GP satisfaction, cancer, early diagnosis, Denmark
Abstract

**Background:** Patients with cancer often consult their general practitioner (GP) prior to the diagnosis. Thus, actions taken by the GP are crucial for optimisation of cancer care. This study aimed to investigate the association between cancer patient’s travel distance to the first specialised diagnostic investigation and the GP’s diagnostic strategy and satisfaction with the waiting time and the availability of diagnostic investigations.

**Method:** This combined questionnaire- and registry-based study included incident cancer patients diagnosed in the last six months of 2016 where the GP had been involved in the diagnostic process of the patients prior to their diagnosis of cancer (n=3,455). The patient’s travel distance to the first specialised diagnostic investigation was calculated by ArcGIS Network Analyst. The diagnostic strategy of the GP and the GP’s satisfaction with the waiting times and the available investigations were assessed from GP questionnaires.

**Results:** The patient’s travel distance to the first specialised diagnostic investigation was not associated with the diagnostic strategy of the GP. However, when the GP did not suspect cancer or serious illness, a tendency was seen that longer travel distance to the first specialised diagnostic investigation increased the likelihood of the GP using ‘wait-and-see’ approach and ‘medical treatment’ as diagnostic strategies. The GPs of patients with travel distance longer than 49 kilometres to the first specialised diagnostic investigation were more likely to report dissatisfaction with the waiting time for requested diagnostic investigations (PRR: 1.98, 95% CI: 1.20-3.28).

**Conclusion:** A tendency to use ‘wait-and-see’ and ‘medical treatment’ were more likely in GPs of patients with long travel distance to the first diagnostic investigation when the GP did not suspect cancer or serious illness. Long distance was associated with higher probability of GP dissatisfaction with the waiting time for diagnostic investigations.

**Background**

Western healthcare systems have increasingly centralised and specialised healthcare services over the recent decades [1, 2]. Consequently, a large proportion of patients have longer distance to cancer diagnostic investigations [3]. In countries with a gatekeeping system, GPs may have to consider long
distances when referring patients to specialised care [4].

The literature is inconclusive on the potential impact of distance to diagnostic services on cancer outcomes. Some studies have suggested that longer distance to healthcare services or rural residence are associated with poorer cancer prognosis [5–8]. Others have reported better prognosis in patients with long distance to healthcare services or rural residence [9, 10]. Some studies have found no association [11, 12]. Our research group has found that the association between distance to cancer diagnostics and diagnostic delays in the cancer trajectory depends on the diagnostic difficulty of the underlying cancer [13]. Other studies, including a few qualitative studies, have attempted to establish the direction and the magnitude of the impact of distance on cancer outcomes [14, 15], but possible explanations remain understudied.

GPs play a crucial role in early cancer detection because the majority of cancer patients initially consult their GP with symptoms [16, 17]. In approximately 50% of patients who begin the diagnostic journey in general practice, the GP will suspect cancer at the first presentation [18]. The GP often has a range of strategies available for further relevant diagnostics including in-house options as “wait-and-see”, blood tests and medical treatment. The GP can also act as a gatekeeper to e.g. specialised private practices, Cancer Patient Pathways (CPP) or diagnostic imaging (e.g. CT scan). Therefore, the actions taken by the GP upon the patient’s symptom presentation may considerably affect the cancer trajectory [16]. Nevertheless, it is unknown if the GP’s diagnostic strategy is affected by the patient’s travel distance to cancer diagnostic investigations. Furthermore, we do not know whether this travel distance may affect the GP’s satisfaction with the access to and waiting time for diagnostic investigations.

Methods
The aim of this study was to analyse whether the travel distance from the patient’s residential address to the medical facility performing the first cancer diagnostic investigation is associated with the GP’s chosen diagnostic strategy and the GP’s satisfaction with the access to and waiting time for diagnostic investigations.

Study design and setting
This nationwide observational study based on combined questionnaire- and registry data was conducted in Denmark with a population of 5.8 million in 2018. The healthcare system is tax-funded and offers free access to healthcare for all citizens. The GP acts as a gatekeeper serving as the first point of contact to the healthcare system, and 99% of the Danish population is registered with a general practice, which must be consulted for medical advice [19]. GPs can refer patients to investigations and treatment at hospitals and private practicing specialists. CPPs have been implemented for more than 30 types of cancer to ensure standardised national guidelines on the diagnostics and treatment of cancer [20].

Participants
The study population was defined as patients aged 30–99 years recorded with an incident cancer diagnosis (excluding ICD-10: C44) between 1 July and 20 December 2016 in the Danish National Patient Register (NPR) [21].

Patients were eligible if a first registered cancer related investigation could be assessed in Danish nationwide registers and two data sources were used. First, patients undergoing a first diagnostic investigation at a specialised private practice (gynaecology, ear-nose-throat specialist, eye specialist or dermatologist) were identified in the National Health Insurance Service Register (NHISR) (specialty codes: 04, 07, 15, 16, 19, 21, 39, 41). These specialties serve as filter functions in a number of CPPs often referred by a GP. Contacts up to three months prior to diagnosis were assessed in the NHISR, and the first registered contact in this period was selected. Second, patients for whom no diagnostic investigations had been recorded in the NHISR were identified through hospital contacts recorded in the NPR [21]. We identified contacts to the hospital for up to three months prior to the date of diagnosis and selected the first relevant contact (an ICD-10 DC or DZ code, excluding Z08-Z09, Z20-Z29, Z30-Z39, Z55-Z65, Z70-Z76).

The GPs of the included patients received a questionnaire between 28 April 2017 and 10 January 2018 for each patient who had given consent to contact their GP. If the patient had deceased shortly after the diagnosis, permission to contact was granted by the Danish Patient Safety Authority [22]. Each GP was asked to fill in the questionnaire based on the medical records. The questionnaire focussed on
the following themes: milestone dates in the cancer trajectory, diagnostic strategy, routes to diagnosis and satisfaction with diagnostic procedures [23]. A GP could fill in questionnaires for more than one patient.

The inclusion criteria were: 1) the GP had completed the questionnaire, 2) the GP was involved in the diagnostic process. Thus, GP responses of 3,455 patients were eligible for inclusion in the study.

Data sources
All data sources were linked through the patient’s unique civil registration number (CRN), which is allocated to all Danish residents and used at every contact with the healthcare system [24]. Information on the GP’s diagnostic strategy and level of satisfaction with diagnostic investigations was obtained from the GP questionnaire.

Variables
Diagnostic strategy was assessed from the question, “Which actions did you/your practice take in the time from when the patient first contacted your practice until you/your practice referred the patient for further investigations for the first time?” The following actions were studied in the analyses: 1) wait-and-see approach (yes/no), 2) medical treatment (yes/no) and 3) referral to further diagnostic investigation on the same day (yes/no). Referral can either be to a CPP, diagnostic unit, specialised private practice, diagnostic imaging or other laboratory test at the hospital. For this study, referral was investigated in general terms and not distinguished between different referral modalities as this depend on e.g. the patients symptoms and the GPs options for referral.

Satisfaction with waiting time and available diagnostic investigations was assessed from the two following questions regarding the diagnostic workup of the patient in general practice: “How satisfied were you with the availability of diagnostic investigations?” “How satisfied were you with the waiting time for diagnostic investigations?” The response categories “very satisfied” and “satisfied” were combined into “satisfied”, and “dissatisfied” and “very dissatisfied” were combined into “dissatisfied”. The response category “do not know/not relevant” was omitted. The availability of diagnostic investigations vary across regions in Denmark and the GP answered these questions based on his or her availability.
Travel distance (shortest road distance) between patient’s residential address on the date of diagnosis and the first diagnostic investigation in the cancer trajectory was calculated by ArcGIS Network Analyst [25]. This information was obtained from the Danish Civil Registration System [24]. Distance to the first diagnostic investigation was calculated for 3,231 patients (first contact to a hospital: 87%; first contact to a specialised private practice: 13%). To avoid possible outliers or inclusion of erroneous registrations, it was chosen to exclude patients with a distance of more than 100 km to the first diagnostic investigation (n = 76), as it is unlikely in Denmark that the first relevant diagnostic investigation is so far from the patients residence. Thus, 3,155 patients were included in the analysis.

Confounders
The following variables were included as potential confounders based on data from Statistics Denmark: age, sex, patient’s education categorised according to UNESCO’s International Standard Classification of Education [26] (low: ≤10 years, middle: >10 ≤ 15 years and high: >15 years) and patient’s marital status (married/cohabiting or living alone). Information on cancer type was obtained from the NPR and included as a potential confounder categorised into: 1) breast cancer, 2) gynaecological cancer, 3) cancer in male genitals, 4) cancer in the digestive organs, 5) cancer in the respiratory system, 6) malignant melanoma, 7) haematological cancer or lymphomas and 8) other types of cancer.

Statistical analysis
Generalised linear models (GLMs) with prevalence rate ratios (PRRs) and 95% confidence intervals (CI) were applied to study the association between travel distance from patient’s residence to the first specialised diagnostic investigation and the GP’s diagnostic strategy and satisfaction with available diagnostic investigations. Distance to the medical facility performing the first specialised diagnostic investigation was categorised into the 25%, 50%, 75% and 90% centiles, corresponding to 0–6 km, > 6–18 km, > 18–34 km, > 34–49 km and > 49 km.

The association between the travel distance to the first diagnostic investigation and the GP’s diagnostic strategy and satisfaction with the waiting time was studied using an unadjusted model,
which was followed by a model adjusted for patient’s sex, age, education, marital status and cancer type. To assess if the association between travel distance and GP’s diagnostic strategy was modified by the GP’s suspicion of cancer, we further stratified the analyses on “wait-and-see”, “medical treatment” and “same-day referral” according to whether or not the GP suspected cancer or serious illness. Prior to this, it was tested if distance was associated with the GPs suspicion of cancer or serious illness, which was not the case.

Stata statistical software, release 15.0, was used for all analyses.

Results
Participants and descriptive data
Among the 3,155 included patients, the median age was 70 years, the majority were male, had middle-level education and were married (Table 1). The GP suspected cancer or serious illness in 64% of the patients at first presentation. Half of the patients lived within 18 km of the medical facility performing their first specialised diagnostic investigation (Table 1).
Table 1
Socio-economic position and patient’s travel distance to first specialised cancer investigation in the study population (numbers vary due to missing data)

|                          | N    | (%)  |
|--------------------------|------|------|
| Total                    | 3,155| (100) |
| Age, median (IQR)        | 70 (61–76) |      |
| Sex                      |      |      |
| Female                   | 1,507| (47.8)|
| Male                     | 1,648| (52.2)|
| Education                |      |      |
| Low                      | 996  | (32.4)|
| Middle                   | 1,399| (45.5)|
| High                     | 678  | (22.1)|
| Marital status           |      |      |
| Married/cohabiting       | 1,976| (63.4)|
| Living alone             | 1,143| (36.6)|
| GP’s suspicion of cancer or serious illness | | |
| No                       | 1,084| (35.0)|
| Yes                      | 2,013| (64.0)|
| Cancer type              |      |      |
| Breast cancer            | 448  | (14.2)|
| Gynaecological cancer    | 165  | (5.2) |
| Cancer in the male genitals | 491 | (15.6)|
| Cancer in the digestive system | 726 | (23.0)|
| Cancer in the respiratory system | 443 | (14.0)|
| Haematological cancer and lymphomas | 227 | (7.2) |
| Malignant melanoma       | 237  | (7.5) |
| Others                   | 418  | (13.3)|
| Distance* (km), median (IQR) | 18 (6–34) | | |
| Distance* (km) categorical | | |
| 0–6                      | 785  | (25.0) |
| >6–18                    | 778  | (24.7) |
| >18–34                   | 778  | (24.7) |
| >34–49                   | 493  | (15.6) |
| >49                      | 321  | (10.2) |

* Travel distance from the residence of the patient to the patient’s first specialised cancer investigation

Outcome: patient’s travel distance and GP’s diagnostic strategy

No significant associations were observed between the patient’s travel distance to the first specialised diagnostic investigation and the GP’s diagnostic strategy (Table 2). When the GP did not suspect cancer, there was a tendency that travel distance of more than 6 km to the patient’s first diagnostic cancer investigation was associated with higher likelihood of the GP selecting ‘wait-and-see’ and ‘medical treatment’ as diagnostic strategy. However, this was only statistically significant in the distance category > 6–18 km for ‘wait-and-see’ and in the category > 18–34 km for ‘medical treatment’ (Table 3).
The association between patient’s travel distance to the first specialised diagnostic investigation and the probability of the GP using “wait-and-see”, “medical treatment” and “referral the same day” (i.e. the diagnostic strategy of the GP)

| Distance* (km) | Wait-and-see | Medical treatment | Referred the same day |
|---------------|--------------|-------------------|----------------------|
|               | N<sub>yes</sub> | PRR<sub>unadj</sub> (95%CI) | PRR<sub>adj**</sub> (95%CI) | N<sub>yes</sub> | PRR<sub>unadj</sub> (95%CI) | PRR<sub>adj**</sub> (95%CI) | N<sub>yes</sub> | PRR<sub>unadj</sub> (95%CI) | PRR<sub>adj**</sub> (95%CI) |
| 0–6          | 77           | 1 (ref.)          | 1 (ref.)             | 76           | 1 (ref.)          | 1 (ref.)             | 461          | 1 (ref.)          | 1 (ref.)             |
| >6–18        | 91           | 1.19 (0.89–1.59)  | 1.18 (0.89–1.58)     | 87           | 1.16 (0.86–1.55)  | 1.18 (0.88–1.58)     | 430          | 0.94 (0.86–1.03)  | 0.95 (0.88–1.10)     |
| >18–34       | 75           | 0.89 (0.73–1.33)  | 0.96 (0.70–1.30)     | 88           | 1.17 (0.87–1.56)  | 1.19 (0.90–1.60)     | 445          | 0.97 (0.90–1.06)  | 0.98 (0.92–1.04)     |
| >34–49       | 44           | 0.91 (0.64–1.29)  | 0.90 (0.64–1.29)     | 51           | 1.07 (0.76–1.50)  | 1.14 (0.81–1.59)     | 305          | 1.05 (0.96–1.15)  | 0.96 (0.89–1.03)     |
| >49          | 40           | 1.27 (0.89–1.82)  | 1.16 (0.80–1.68)     | 39           | 1.25 (0.87–1.81)  | 1.31 (0.91–1.87)     | 183          | 0.97 (0.87–1.09)  | 0.98 (0.90–1.06)     |

* Adjusted for sex, age (continuous), education, marital status and cancer type
** Travel distance from the residence of the patient to the first specialised investigation

Table 3

The association between patient’s travel distance to first specialised diagnostic investigation and the probability of the GP using “wait-and-see”, “medical treatment” and “referral the same day” (i.e. the diagnostic strategy of the GP) stratified on whether the GP suspected cancer or serious illness or not

| Distance* (km) | Wait-and-see** | Medical treatment** | Referred the same day** |
|---------------|---------------|-------------------|-----------------------|
|               | GP did suspect cancer or serious illness (n = 2013) | GP did not suspect cancer or serious illness (n = 1084) | GP did suspect cancer or serious illness (n = 2013) | GP did not suspect cancer or serious illness (n = 1084) | GP did suspect cancer or serious illness (n = 2013) | GP did not suspect cancer or serious illness (n = 1084) |
|               | PRR<sub>adj</sub> (95%CI) | PRR<sub>adj</sub> (95%CI) | PRR<sub>adj</sub> (95%CI) | PRR<sub>adj</sub> (95%CI) | PRR<sub>adj</sub> (95%CI) | PRR<sub>adj</sub> (95%CI) |
| 0–6          | 1 (ref.) | 1 (ref.) | 1 (ref.) | 1 (ref.) | 1 (ref.) |
| >6–18        | 0.95 (0.45–1.91) | 1.48 (1.08–2.04) | 0.92 (0.51–1.64) | 1.25 (0.91–1.72) | 0.97 (0.90–1.04) | 0.82 (0.63–1.08) |
| >18–34       | 0.84 (0.42–1.67) | 1.15 (0.82–1.61) | 0.88 (0.47–1.58) | 1.45 (1.05–1.99) | 0.99 (0.92–1.06) | 0.84 (0.64–1.12) |
| >34–49       | 0.44 (0.16–1.19) | 1.19 (0.84–1.60) | 1.09 (0.58–2.04) | 1.29 (0.89–1.87) | 1.04 (0.97–1.12) | 0.86 (0.62–1.19) |
| >49          | 1.21 (0.52–2.79) | 1.21 (0.81–1.82) | 1.05 (0.50–2.21) | 1.29 (0.88–1.91) | 1.01 (0.92–1.11) | 1.07 (0.78–1.46) |

Analysis were based on 3097 patients, due to missing responses regarding GP’s suspicion of cancer
* Adjusted for sex, age (continuous), education, marital status and cancer type
** Travel distance from the residence of the patient to the first specialised investigation

Outcome: patient’s travel distance and GP’s satisfaction with investigations

GPs of patients with a distance of more than 49 km to the first diagnostic investigation were more likely to report dissatisfaction with the waiting time for diagnostic investigations (PRR<sub>adj</sub> 1.98, 95% CI: 1.20–3.28). There was also a statistically insignificant tendency that GPs of patients with a distance of more than 49 km to the first diagnostic investigation were more likely to report dissatisfaction with the availability of diagnostic investigations (Table 4).
Table 4
The association between patient’s travel distance to the first diagnostic investigation and the probability of the GP being dissatisfied with diagnostic investigations

| GP’s dissatisfaction with: | Availability of diagnostic investigations | Waiting time for diagnostic investigations |
|---------------------------|------------------------------------------|----------------------------------------------|
|                           | N_{dissatisfied} | PRR_{unadj} | PRR_{adj**} | N_{dissatisfied} | PRR_{unadj} | PRR_{adj**} |
| Distance *(km)            |               |            |            |               |            |            |
| 0–6                      | 17            | 1 (ref.)   | 1 (ref.)   | 33            | 1 (ref.)   | 1 (ref.)   |
| >6–18                    | 15            | 0.89 (0.45–1.77) | 0.91 (0.46–1.80) | 43            | 1.33 (0.86–2.07) | 1.33 (0.85–2.08) |
| >18–34                   | 9             | 0.52 (0.23–1.16) | 0.58 (0.26–1.30) | 28            | 0.87 (0.53–1.42) | 0.90 (0.55–1.49) |
| >34–49                   | 8             | 0.74 (0.32–1.70) | 0.89 (0.38–2.06) | 21            | 1.00 (0.59–1.71) | 1.07 (0.62–1.84) |
| >49                      | 12            | 1.72 (0.83–3.56) | 1.89 (0.90–3.85) | 24            | 1.86 (1.12–3.09) | 1.98 (1.20–3.28) |

* Travel distance from the residence of the patient to the first specialised investigation
**Adjusted for sex, age (continuous), education, marital status, cancer type and cancer type

Discussion

Key results

When GPs did not suspect cancer or serious illness at first presentation, there was a tendency that patient’s travel distance to the first diagnostic cancer investigation was associated with the GP using ‘wait-and-see’ or ‘medical treatment’ as initial diagnostic strategy. This tendency was not observed when combining all cancer patients, regardless of the GP’s suspicion of cancer. Furthermore, when the patient’s travel distance to the first specialised diagnostic investigation exceeded 49 km, lower GP satisfaction was seen with the waiting time for GP-requested diagnostic investigations.

Strengths and limitations

The assessment of the GP’s diagnostic strategy and the level of satisfaction was based on responses from a national questionnaire survey among GPs of newly diagnosed patients, and the identification of patients was based on the NPR, which is known to have valid and complete data [21]. The GPs were asked to check their medical records when responding to the questionnaire. Hence, even though the questionnaire was answered in retrospect, the risk of recall bias was minimised. The inclusion of GPs was determined by patients approving the inclusion of their GP in the study, except for GPs with patients who had deceased shortly after the diagnosis. It is likely that non-responding patients were more likely to have lower socio-economic status (SEP). GPs of patients with low SEP might thus have been less representative in the study. Still, this has been shown not to bias outcome estimates markedly [27].

We used valid and complete registers to obtain information on SEP and cancer type of the patients...
The first diagnostic investigation was also based on registry information from hospitals [21] and specialised private practices [29]; this information was identified in the registers based on an algorithm assessing contacts in the healthcare system three months prior to the diagnosis. Misclassification cannot be ruled out as the first diagnostic investigation might have been performed prior to this period. As the patient’s travel distance and the GP’s diagnostic strategy and satisfaction level are unknown for this group, it is not straightforward to predict the potential bias. We believe that the group affected by this potential bias is minimal, as previous work has found that 75% of all cancer patients are diagnosed within 73 days of first referral [30].

When referring to a CPP including a filter function (e.g. gynaecological CPPs), the referral is organised in a central administration and the GP may not know which hospital or practice the patient is referred to. Hence, as the patient’s travel distance is unknown to the GP, the diagnostic strategy cannot be influenced by this knowledge. However, a sensitivity analysis indicated similar results when we excluded cases often diagnosed through a CPP using filter functions (gynaecological cancer, ear-nose-throat cancer, eye cancer or malignant melanoma) (data not shown).

The study did not distinguish between which type of referral the GP applied (e.g. CPP, imaginal diagnostic at the hospital etc.), but classified “referral for further diagnostics on the first day” as one. This was chosen due to considerations about sample size and because the available diagnostic investigations vary somewhat across the regions and hospitals in Denmark. Thus, not all GPs have direct access to CT scan and data was not available on which investigations each GP had access too. All GPs can however refer to CPP’s, and it could be interesting to assess if distance modified the use of CPP.

High ceiling effect was seen for some of the responses, and few responses were available in some of the categories. Consequently, type II errors cannot be ruled out (e.g. in the stratified analysis on ‘wait-and-see’ and ‘medical treatment’). This could explain why the findings did not reach statistical significance for all categories in these analyses. Consequently, the results should be interpreted with caution and larger-scale studies are required to establish an association. However, to our knowledge no other studies have been carried out to study how distance is associated with the GP’s diagnostic
strategies and this study indicate that GP’s of patient with longer distance to further cancer diagnostics more often use “wait-and-see” and “medical treatment” if cancer or serious illness is not the first suspicion of the GP.

Interpretation

Previous studies have investigated factors of importance for the GP’s propensity to refer patients for cancer diagnostics. The literature suggests that important factors for the GP’s choice of action at first consultation include organisational factors, such as funding system and access to investigations, and contextual factors, such as symptomology and relationship with specialist colleagues [4, 18, 31]. Thus, the diagnostic strategy of the GP, including direct referral or wait-and-see, appears to be multifaceted and to depend on the specific healthcare system, as suggested by a recent study [4].

Travel distance to medical consultations and accessibility of GPs are central topics in many healthcare systems due to shortage of GPs and increasing centralisation, which may further increase the patient’s travel distance to cancer diagnostics and treatment [1–3, 32]. A study from 2018 combining results on GP referral modalities in 20 countries found that the GPs in 56% of the responding countries agreed that their patients often had to travel long distances to consult a medical specialist [4], but it remains unclear how increasing travel distance to specialist medical care may affect cancer outcomes [5–12]. Few studies have explored underlying factors behind the potential association between travel distance and cancer outcome [14, 15]. To our knowledge, this is the first study to investigate how the patient’s travel distance to the first diagnostic investigation influences the GP’s diagnostic strategy. Thereby, it is also one of the first studies attempting to investigate how the patient’s travel distance and related underlying mechanisms may influence cancer outcome. In the combined analysis, travel distance did not seem to affect the GP’s diagnostic strategy. However, when stratifying the analysis on the GP’s suspicion of cancer, we found a tendency that increasing travel distance for the patient was associated with increasing use of ‘wait-and-see’ and ‘medical treatment’ when the GP did not suspect cancer. It is a positive factor that the GP’s diagnostic strategy was not influenced by patient’s travel distance when the GP did suspect cancer. However, although the results were ambiguous, the
tendency for GPs to use ‘wait-and-see’ for patients with increasing distance to cancer diagnostic facilities indicates that GPs may indeed be affected by the distance to a relevant cancer facility. As all of these patients were cancer patients in this study, this finding should be elaborated further in larger studies.

Increasing travel distance to the patient’s first diagnostic investigation was associated with higher GP dissatisfaction with the waiting time for requested diagnostic investigations. This was only found for GPs with patients having more than 49 km between their residential address and the medical facility performing the diagnostic investigation; this could suggest signs of barriers in general practices remotely located from large hospitals. This dissatisfaction might be rooted in communication barriers between primary and secondary care. Previous studies have pointed to the importance of well-established communication between primary and secondary care for optimal diagnostics [33–35]. Further studies are needed to explore if the findings in the present study are linked to communication barriers or other factors affecting the GP’s perception of waiting time. These studies should also take into account the variability in referral options for the GPs. E.g. not all Danish GPs have the possibility to refer directly to CT scan. It is unknown how this affect the GP’s assessment of available investigations.

Conclusion
This study found a tendency for GPs to use ‘wait and see’ and ‘medical treatment’ as diagnostic strategy when cancer or serious illness is not suspected in patients with long travel distance to the medical facility performing the first diagnostic investigation. However, this tendency was not observed when the GP did suspect cancer. Longer distance was associated with higher GP dissatisfaction with the waiting time for diagnostic investigations. Further studies with larger samples are required to establish the association.

Abbreviations
CI Confidence interval
CPP Cancer patient pathway
CRN Civil registration number
Declarations

_Ethical approvals and consent to participate_

According to Danish law, this study did not need approval by the Committee on Health Research Ethics as the study was based solely on questionnaire and registry data [36]. The project “Geographic variations and cancer outcomes” (ID 189) has been approved and is registered in the Record of Processing Activities at the Research Unit for General Practice in Aarhus in accordance with the provisions of the General Data Protection Regulation (GDPR). In CaP 3 the consent by the patient and GP was obtained by answering the questionnaire following Danish regulation at the time (2010). The patients of CaP6 signed a consent to use their responses and to contact their GP. In accordance with § 46 of the Danish Health Act, the Danish Patient Safety Authority gave us permission to obtain information (by questionnaires) from the GPs’ medical records for patients who deceased shortly after their diagnosis (case no. 3-3013-1956/1).

_Competing interests_

The authors declare that there are no conflicts of interests.

_Funding_

This project was funded by the Danish Cancer Society and the Health Foundation (Danish: Helsefonden). The funding sources were not involved in the planning or conduction of the analysis,
interpretation of results or writing of the paper.

Acknowledgements

Not Applicable

Availability of data and materials

Data used for this study is not public available according to Danish laws.

Author contributions

LFV, LH and PV conceived the idea and contributed with input, interpretations of the results and the contents of the paper. LFV was responsible for drafting the manuscript and for the statistical analyses. All authors read and approved the final version of the manuscript.

References

1. Olejaz M, Juul Nielsen A, Rudkjøbing A, Birk H, Krasnik A, Hernández-Quevedo C: Denmark Health System review. Health Systems in Transition 2012, 14(2):1.

2. Micheli A, Coebergh JW, Mugno E, Massimiliani E, Sant M, Oberaigner W, Holub J, Storm HH, Forman D, Quinn M et al: European health systems and cancer care. Ann Oncol 2003, 14 Suppl 5:v41-60.

3. Kelly C, Hulme C, Farragher T, Clarke G: Are differences in travel time or distance to healthcare for adults in global north countries associated with an impact on health outcomes? A systematic review. BMJ open 2016, 6(11):e013059-012016-013059.

4. Harris M, Vedsted P, Esteva M, Murchie P, Aubin-Augier I, Azuri J, Brekke M,
Buczkowski K, Buono N, Costiug E et al: **Identifying important health system factors that influence primary care practitioners’ referrals for cancer suspicion: a European cross-sectional survey.** *BMJ Open* 2018, 8(9):e022904.

5. Jones AP, Haynes R, Sauerzapf V, Crawford SM, Zhao H, Forman D: **Travel times to health care and survival from cancers in Northern England.** *Eur J Cancer* 2008, 44(2):269-274.

6. Massarweh NN, Chiang YJ, Xing Y, Chang GJ, Haynes AB, You YN, Feig BW, Cormier JN: **Association between travel distance and metastatic disease at diagnosis among patients with colon cancer.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2014, 32(9):942-948.

7. Campbell NC, Elliott AM, Sharp L, Ritchie LD, Cassidy J, Little J: **Rural and urban differences in stage at diagnosis of colorectal and lung cancers.** *British journal of cancer* 2001, 84(7):910-914.

8. Nguyen-Pham S, Leung J, McLaughlin D: **Disparities in breast cancer stage at diagnosis in urban and rural adult women: a systematic review and meta-analysis.** *Annals of Epidemiology* 2014, 24(3):228-235.

9. Xu Z, Becerra AZ, Justiniano CF, Boodry CI, Aquina CT, Swanger AA, Temple LK, Fleming FJ: **Is the Distance Worth It? Patients With Rectal Cancer Traveling to High-Volume Centers Experience Improved Outcomes.** *Diseases of the colon and rectum* 2017, 60(12):1250-1259.

10. Murage P, Murchie P, Bachmann M, Crawford M, Jones A: **Impact of travel time and rurality on presentation and outcomes of symptomatic colorectal cancer: a cross-sectional cohort study in primary care.** *The British journal of general practice : the journal of the Royal College of General Practitioners* 2017.

11. Gunderson CC, Nugent EK, McMeekin DS, Moore KN: **Distance traveled for...**
treatment of cervical cancer: who travels the farthest, and does it impact outcome? International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2013, 23(6):1099-1103.

12. Hines RB, Markossian TW: Differences in late-stage diagnosis, treatment, and colorectal cancer-related death between rural and urban African Americans and whites in Georgia. The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association 2012, 28(3):296-305.

13. Flytkjaer Virgilsen L, Moller H, Vedsted P: Cancer diagnostic delays and travel distance to health services: A nationwide cohort study in Denmark. Cancer epidemiology 2019, 59:115-122.

14. Bain NS, Campbell NC: Treating patients with colorectal cancer in rural and urban areas: a qualitative study of the patients' perspective. Family practice 2000, 17(6):475-479.

15. Brundisini F, Giacomini M, DeJean D, Vanstone M, Winsor S, Smith A: Chronic disease patients' experiences with accessing health care in rural and remote areas: a systematic review and qualitative meta-synthesis. Ontario health technology assessment series 2013, 13(15):1-33.

16. Allgar VL, Neal RD: General practitioners' management of cancer in England: secondary analysis of data from the National Survey of NHS Patients-Cancer. European journal of cancer care 2005, 14(5):409-416.

17. Hansen RP, Vedsted P, Sokolowski I, Sondergaard J, Olesen F: Time intervals from first symptom to treatment of cancer: a cohort study of 2,212 newly diagnosed cancer patients. BMC health services research 2011, 11:284-6963-6911-6284.
18. Jensen H, Torring ML, Olesen F, Overgaard J, Vedsted P: **Cancer suspicion in general practice, urgent referral and time to diagnosis: a population-based GP survey and registry study.** *BMC Cancer* 2014, **14**:636.

19. Pedersen KM, Andersen JS, Sondergaard J: **General practice and primary health care in Denmark.** *Journal of the American Board of Family Medicine: JABFM* 2012, 25 Suppl 1:S34-38.

20. Probst HB, Hussain ZB, Andersen O: **Cancer patient pathways in Denmark as a joint effort between bureaucrats, health professionals and politicians--a national Danish project.** *Health policy (Amsterdam, Netherlands)* 2012, **105**(1):65-70.

21. Lynge E, Sandegaard JL, Rebolj M: **The Danish National Patient Register.** *Scandinavian Journal of Public Health* 2011, 39(7 Suppl):30-33.

22. **The Danish Patient Safety Authority** [https://stps.dk/en/]

23. Society DC: [In Danish: Kræftpatienters behov og oplevelser med sundhedsvæsenet under udredning og behandling]. In. Copenhagen; 2017.

24. Pedersen CB: **The Danish Civil Registration System.** *Scandinavian Journal of Public Health* 2011, 39(7 Suppl):22-25.

25. Esri: **ArcGIS Network Analyst.** In., vol. 2014; 2014.

26. UNESCO: **ISCED: International Standard Classification of Education.** In., vol. 2014; 2014.

27. Nohr EA, Frydenberg M, Henriksen TB, Olsen J: **Does low participation in cohort studies induce bias?** *Epidemiology (Cambridge, Mass)* 2006, **17**(4):413-418.

28. Gjerstorff ML: **The Danish Cancer Registry.** *Scandinavian Journal of Public Health* 2011, 39(7 Suppl):42-45.

29. Andersen JS, Olivarius Nde F, Krasnik A: **The Danish National Health Service**
Register. Scandinavian Journal of Public Health 2011, 39(7 Suppl):34-37.

30. Jensen H, Torring ML, Olesen F, Overgaard J, Fenger-Gron M, Vedsted P: Diagnostic intervals before and after implementation of cancer patient pathways - a GP survey and registry based comparison of three cohorts of cancer patients. BMC cancer 2015, 15(1):308-015-1317-1317.

31. Mitchell E, Macdonald S, Campbell NC, Weller D, Macleod U: Influences on pre-hospital delay in the diagnosis of colorectal cancer: a systematic review. Br J Cancer 2008, 98(1):60-70.

32. Majeed A: Shortage of general practitioners in the NHS. Bmj 2017, 358:j3191.

33. Sampson R, Barbour R, Wilson P: The relationship between GPs and hospital consultants and the implications for patient care: a qualitative study. BMC Fam Pract 2016, 17:45.

34. Farquhar MC, Barclay SI, Earl H, Grande GE, Emery J, Crawford RA: Barriers to effective communication across the primary/secondary interface: examples from the ovarian cancer patient journey (a qualitative study). Eur J Cancer Care (Engl) 2005, 14(4):359-366.

35. Green T, Atkin K, Macleod U: Cancer detection in primary care: insights from general practitioners. Br J of Cancer 2015(112):S41–S49.

36. The Danish Ethics Commettee. What need to be reported? [In Danish: Hvad skal anmeldes?] Accessed at: http://www.nvk.dk/forsker/naar-du-anmelder/hvilke-projekter-skal-jeg-anmelde